Clinical perspectives for irreversible tyrosine kinase inhibitors in cancer.
Parma, Italy. In Biochem Pharmacol, Jan 2013
Different irreversible tyrosin kinase inhibitors directed against epidermal growth factor receptor (EGFR), Bruton's tyrosine kinase (BTK), vascular endothelial growth factor receptor (VEGFR) and fibroblast growth factor receptor tyrosine kinase (FGFR) have been developed and some of them have been employed clinically as anticancer agents.
B-cell receptor pathobiology and targeting in NHL.
Nashville, United States. In Curr Oncol Rep, Oct 2012
With the tremendous insight gained in the last 2 decades from basic science research, our understanding of the pathobiology of the B-cell receptor is leading to the discovery and clinical development of many new therapeutic targets such as Syk, Bruton's tyrosine kinase, and phosphatidylinositol 3-kinase.